Study population
thromboembolic, hypertension, anemia
CARDIAC DISEASES, GESTATIONAL DIABETES MELLITUS, COMPLICATIONS, DISORDERS, ANEMIA, BLEEDING TENDENCY, VASCULAR DISEASES, THYROID DISEASES, HYPERTENSION, DISEASES, PREECLAMPSIA
The inclusion criteria were: all pregnant women in labor aged from 30 to 50 years old, completed 38 gestational weeks without obvious complications, had a good general condition, were free of other gynecological or obstetric problems, had acceptable investigation results, and would undergo CS. We excluded pregnant women who had any complications during pregnancy such as all hypertension disorders, gestational diabetes mellitus, preeclampsia, anemia, thyroid diseases, cardiac diseases, vascular diseases, previous thromboembolic effects, and bleeding tendency diseases. All women who were admitted to the four hospitals between October 2020 and December 2020 and matched the inclusion criteria were included and randomized into the three groups: the first group received oxytocin, the second group received tranexamic acid with ethamsylate, and the third received a placebo.